Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial

ConclusionIn patients undergoing primary PCI, aCYP2C19 genotype-guided strategy compared with standard treatment with ticagrelor or prasugrel resulted in QALYs gained and cost savings.Trial RegistrationClinicaltrials.gov number: NCT01761786, Netherlands trial register number: NL2872
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research